| 000 | 01738 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518064125.0 | ||
| 264 | 0 | _c20201104 | |
| 008 | 202011s 0 0 eng d | ||
| 022 | _a1520-5126 | ||
| 024 | 7 |
_a10.1021/jacs.9b09848 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSu, Hao | |
| 245 | 0 | 0 |
_aMacrocyclization of a Class of Camptothecin Analogues into Tubular Supramolecular Polymers. _h[electronic resource] |
| 260 |
_bJournal of the American Chemical Society _c10 2019 |
||
| 300 |
_a17107-17111 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. | ||
| 650 | 0 | 4 | _aAdministration, Intravenous |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadministration & dosage |
| 650 | 0 | 4 |
_aCamptothecin _xanalogs & derivatives |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aCircular Dichroism |
| 650 | 0 | 4 | _aCyclization |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aDrug Liberation |
| 650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHydrophobic and Hydrophilic Interactions |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 | _aMicroscopy, Electron, Transmission |
| 650 | 0 | 4 |
_aNanostructures _xchemistry |
| 650 | 0 | 4 |
_aPolymers _xchemistry |
| 650 | 0 | 4 |
_aWater _xchemistry |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aWang, Feihu | |
| 700 | 1 | _aWang, Yuzhu | |
| 700 | 1 | _aCheetham, Andrew G | |
| 700 | 1 | _aCui, Honggang | |
| 773 | 0 |
_tJournal of the American Chemical Society _gvol. 141 _gno. 43 _gp. 17107-17111 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1021/jacs.9b09848 _zAvailable from publisher's website |
| 999 |
_c30203078 _d30203078 |
||